Harrow Health, Inc. (HROW)
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation.
The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018.
Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
102 Woodmont Boulevard
Nashville, TN 37205
|Phone||615 733 4730|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Mark L. Baum J.D.||Chief Executive Officer and Chairman|
|Andrew R. Boll C.F.A., C.M.A., CFA, CMA||Chief Financial Officer and Corporate Secretary|
|Dr. Robert J. Kammer D.D.S.||Special Advisor|
|John P. Saharek||President of ImprimisRx|
|David Moufarrège||Vice President of Technology|
|Jamie Webb||Director of Communications and Investor Relations|
|Dr. Dennis E Saadeh Pharm.D.||Chief of Formulation Strategy|
|Dr. Larry M. Dillaha||Chief Medical Officer|
|Andrew Livingston||Chief Innovation Officer|
Latest SEC Filings
|Aug 9, 2022||10-Q||Quarterly Report|
|Aug 9, 2022||8-K||Current Report|
|Jun 13, 2022||8-K||Current Report|
|Jun 6, 2022||EFFECT||Notice of Effectiveness|
|May 26, 2022||S-3||Registration statement under Securities Act of 1933|
|May 5, 2022||10-Q||Quarterly Report|
|May 5, 2022||8-K||Current Report|
|Apr 26, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 26, 2022||DEF 14A||Other definitive proxy statements|
|Apr 13, 2022||8-K||Current Report|